PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of molcellbPermissionsJournals.ASM.orgJournalMCB ArticleJournal InfoAuthorsReviewers
 
Mol Cell Biol. 2011 April; 31(7): 1565–1576.
PMCID: PMC3135291

Requirement of c-Jun NH2-Terminal Kinase for Ras-Initiated Tumor Formation[down-pointing small open triangle]

Abstract

The c-Jun NH2-terminal kinase (JNK) signal transduction pathway causes increased gene expression mediated, in part, by members of the activating transcription factor protein (AP1) group. JNK is therefore implicated in the regulation of cell growth and cancer. To test the role of JNK in Ras-induced tumor formation, we examined the effect of compound ablation of the ubiquitously expressed genes Jnk1 plus Jnk2. We report that JNK is required for Ras-induced transformation of p53-deficient primary cells in vitro. Moreover, JNK is required for lung tumor development caused by mutational activation of the endogenous KRas gene in vivo. Together, these data establish that JNK plays a key role in Ras-induced tumorigenesis.

INTRODUCTION

The c-Jun NH2-terminal kinase (JNK) is a member of the MAP kinase group that is activated by cytokines/growth factors and also by exposure to environmental stress (16). Targets of the JNK pathway are represented, in part, by members of the activator protein 1 (AP1) group of transcription factors, including c-Jun, JunB, JunD, and related proteins (16). JNK can phosphorylate the NH2-terminal activation domain of these molecules to promote increased transcription activity (16). Moreover, JNK activation causes increased expression of Jun family proteins (47). JNK therefore acts as a major physiological regulator of AP1-dependent gene expression (16). It is established that AP1-dependent gene expression can contribute to cell proliferation (50). Consequently, the JNK signal transduction pathway may increase cell proliferation, and dysregulated JNK signaling may contribute to cancer.

The role of JNK in cancer has been studied using mouse models. Two of the genes that encode JNK are expressed ubiquitously (Jnk1 and Jnk2), and a third gene (Jnk3) is primarily expressed in the nervous system (16). Studies using Jnk1−/− mice and Jnk2−/− mice have demonstrated that JNK can cause both positive and negative changes in tumor development (16, 48). Thus, compared with wild-type mice, Jnk1−/− mice exhibit decreased (and Jnk2−/− mice exhibit increased) carcinogen-induced skin cancer (11, 42). Moreover, carcinogen-induced hepatocellular carcinoma (28) and Bcr-Abl-induced lymphoma (25) are suppressed in Jnk1−/− mice (but not Jnk2−/− mice). In contrast, studies of glioblastoma, prostate cancer, and lung carcinoma cell lines have identified important roles for JNK2 (but not JNK1) (6, 13, 41, 53). Together, these data confirm that JNK may play a role in cancer development, but the relative roles of the JNK1 and JNK2 isoforms are unclear.

It is established that the Jnk1 and Jnk2 genes exhibit partially redundant functions (14, 15, 30, 46). Studies of compound mutants with ablation of both ubiquitously expressed Jnk genes are therefore required. These studies have been compromised by the early embryonic lethal phenotype of Jnk1−/− Jnk2−/− mice (34). Nevertheless, Jnk1−/− Jnk2−/− murine embryonic fibroblasts (MEF) have been prepared. These cells exhibit an early senescence phenotype that is caused by engagement of the p53 tumor suppressor pathway (14, 46). Immortalized wild-type and JNK-deficient fibroblasts have been isolated using the 3T3 protocol that disrupts the p53 pathway (32). Retroviral transduction assays with ectopic expression of activated Ras demonstrated that both wild-type (WT) and JNK-deficient 3T3 cells can exhibit properties of transformed cells (32). JNK may therefore not be required for Ras-induced transformation, but this conclusion is subject to a number of important caveats. It is likely that the 3T3 immortalization protocol does not cause the same genetic alterations in both WT MEF and Jnk1−/− Jnk2−/− MEF. Moreover, these studies of 3T3 cells expressing ectopic Ras may not be informative for understanding the mechanism of epithelial cell tumor formation by mutational activation of the endogenous KRas gene.

The purpose of this study was to test the requirement of JNK for Ras-induced tumorigenesis. First, we examined whether JNK is required for the Ras-induced transformation of primary MEF with a defined genetic background. Second, we examined the requirement of JNK for epithelial cell transformation using an established model of lung cancer in mice. We report that JNK is critically required for Ras-induced transformation of MEF in vitro and for Ras-induced lung tumor formation in vivo.

MATERIALS AND METHODS

Mice.

We have described Jnk1−/− mice (19), Jnk2−/− mice (52), mice with conditional expression of Jnk1 (14), and mice with conditional expression of KRasG12D (29). Mice with Trp53 gene ablation (18) were provided by Stephen Jones, University of Massachusetts Medical School. Mice with conditional expression of Trp53 (36) were obtained from the Jackson Laboratory (strain B6.129P2-Trp53tm1Brn/J [stock number 008462]). Mice expressing 4-hydroxy-tamoxifen-stimulated Cre (2) were obtained from the Jackson Laboratory [strain B6;129-Gt(ROSA)26Sortm1(cre/ERT)Nat/J (stock number 004847)]. The mice used in this study were backcrossed to the C57BL/6J strain (Jackson Laboratories) and were housed in a facility accredited by the American Association for Laboratory Animal Care (AALAC). The Institutional Animal Care and Use Committee (IACUC) of the University of Massachusetts approved all studies using animals.

Genotype analysis.

Genotype analysis was performed by PCR using genomic DNA as the template. The Jnk1LoxP (1.1-kb) and Jnk1Δ (0.4-kb) alleles were identified using the amplimers 5′-CCTCAGGAAGAAAGGGCTTATTTC-3′ and 5′-GAACCACTGTTCCAATTTCCATCC-3′. The wild-type Jnk1 (460-bp) and knockout Jnk1 (390-bp) alleles were identified using the amplimers 5′-CGCCAGTCCAAAATCAAGAATC-3′, 5′-GCCATTCTGGTAGAGGAAGTTTCTC-3′, and 5′-CCAGCTCATTCCTCCACTCATG-3′. The wild-type Jnk2 (400-bp) and knockout Jnk2 (270-bp) alleles were identified using the amplimers 5′-GGAGCCCGATAGTATCGAGTTACC-3′, 5′-GTTAGACAATCCCAGAGGTTGTGTG-3′, and 5′-CCAGCTCATTCCTCCACTCATG-3′. The wild-type Trp53 (320-bp) and knockout Trp53 (150-bp) alleles were identified using the amplimers 5′-GTGTTTCATTAGTTCCCCACCTTGAC-3′, 5′-ATGGGAGGCTGCCAGTCCTAACCC-3′, 5′-GTGGGAGGGACAAAAGTTCGAGGCC-3′, and 5′-TTTACGGAGCCCTGGCGCTCGATGT-3′. The wild-type Trp53 (288-bp) and Trp53LoxP (370-bp) alleles were identified using the amplimers 5′-AGCACATAGGAGGCAGAGAC-3′ and 5′-CACAAAAACAGGTTAAACCCAG-3′. The Trp53Δ (612-bp) allele was identified using the amplimers 5′-CACAAAAACAGGTTAAACCCAG-3′ and 5′-GAAGACAGAAAAGGGGAGGG-3′. The wild-type KRas (285-bp), KRasG12D (315-bp), and KRasLSL-G12D (600-bp) alleles were identified using the amplimers 5′-GGGTAGGTGTTGGGATAGCTG-3′ and 5′-TCCGAATTCAGTGACTACAGATGTACAGAG-3′. The Rosa26 (600-bp) and Rosa26-CreERT (300-bp) alleles were identified using the amplimers 5′-GCGAAGAGTTTGTCCTCAACC-3′, 5′-GGAGCGGGAGAAATGGATATG-3′, and 5′-AAAGTCGCTCTGAGTTGTTAT-3′.

Tumor assays.

Lung tumors were studied in mice with conditional expression of KRasG12D. Lung-specific expression of KRasG12D was studied using calcium phosphate precipitated adenovirus-Cre (Gene Transfer Vector Core, University of Iowa; 2.5 × 107 PFU/mouse) and nasal instillation (29). The tumorigenic potential of MEF was examined by subcutaneous injection of 2 × 105 cells in 12-week-old male C57BL/6J mice (Jackson Laboratories).

Cell culture.

Primary mouse fibroblasts (embryonic day 11) were prepared and cultured in Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum, 1% penicillin-streptomycin, and 1% glutamine (Invitrogen). All studies were performed using low-passage primary MEF (<4 passages). Cre-mediated gene ablation was performed by treating MEF with 1 μM 4-hydroxytamoxifen (24 h). Soft agar assays were performed using methods described previously (32). Cell number was measured using a hemocytometer and by staining with crystal violet (32).

Retroviral transduction assays.

The retroviral vectors pWZL-Blast-E-cadherin and pWZL-Blast-dn-cadherin (39) were obtained from Addgene (numbers 18800 and 18804). A human Nox4 cDNA (10) was cloned by blunt-end ligation into the EcoRI site of the retroviral vector pWZL-Blast. Recombinant retroviruses were prepared and employed for transduction assays in MEF (35) by using selection with 5 μg/ml blasticidin (6 days).

Immunoblot analysis.

Cell lysates were examined by probing with antibodies to caspase 3 (Cell Signaling Technology), E-cadherin (Cell Signaling Technology), JNK1/2 (BD Biosciences and R&D Systems), N-cadherin (BD Biosciences), OB-cadherin (Santa Cruz Biotechnology), phospho-JNK (Cell Signaling Technology), poly(ADP-ribose) polymerase (PARP; BD Biosciences), PCNA (Invitrogen), and α-tubulin (Sigma). Immune complexes were detected using enhanced chemiluminescence (NEN).

ELISA.

Multiplexed enzyme-linked immunosorbent assay (ELISA) was performed using a Luminex 200 machine (Millipore). Cell lysates were probed using the BioPlex phosphoprotein and total target assay kit to measure phosphorylated and total JNK, extracellular signal-regulated kinase (ERK), p38, and AKT (Bio-Rad).

RNA analysis.

Quantitative reverse transcription (RT)-PCR assays (TaqMan) of mRNA expression were performed using a model 7500 fast real-time PCR machine (Applied Biosystems) with total RNA prepared with an RNeasy minikit (Qiagen). The probes were Cdh1 (E-cadherin; Mm01247357_m1), Cyba (p22phox; Mm00514478_m1), Nox4 (Mm00479246_m1 and Hs00276431_m1), Snai1 (Mm00441533_g1), and Snai2 (Slug; Mm00441531_m1) (Applied Biosystems). The relative mRNA expression was normalized by measurement of the amount of Gapdh mRNA in each sample by using TaqMan assays (4352339E; Applied Biosystems).

Reactive oxygen species (ROS) assay.

Cells grown on glass-bottom dishes (MatTek) were pretreated (8 h) without (control) or with 1 μg/ml rotenone (Sigma) or 2.5 μM diphenyleneiodonium chloride (DPI) (Sigma) and then incubated with 10 μM 2′,7′-dichlorodihydrofluorescein diacetate (H2DCFDA) (Invitrogen) for 1 h at 37°C. The cells were washed three times with phosphate-buffered saline (PBS) and imaged using a fluorescence microscope (Zeiss Axiovert). Fluorescence intensity was measured using ImageJ software.

Immunofluorescence analysis.

Cells grown on coverslips were washed with PBS, fixed in 4% paraformaldehyde (15 min), washed with PBS, and then incubated in blocking buffer (0.3% Triton-PBS-5% normal goat serum) for 1 h at 25°C. Incubation with primary antibodies (E-cadherin [Cell Signaling Technology] and N-cadherin [BD Biosciences]) was performed in blocking buffer for 14 h at 4°C. The cells were washed and incubated with secondary antibody (Alexa Fluor 488-conjugated goat anti-mouse or anti-rabbit antibody [Invitrogen]) in blocking buffer for 1 h at 25°C. The coverslips were washed in PBS and mounted using VectaShield medium containing DAPI (4′,6-diamidino-2-phenylindole) (Vector Labs). Images were examined using a Leica TCS SP2 confocal microscope.

DNA fragmentation assays.

Genomic DNA fragmentation was measured using the cell death detection ELISAPLUS kit (Roche) according to the manufacturer's recommendations (35).

Analysis of tissue sections.

Histology was performed using tissue fixed in 10% formalin for 24 h, dehydrated, and embedded in paraffin. Sections (7 μm) were cut and stained using hematoxylin and eosin (Biocare Medical). Immunofluorescence analysis was performed using deparaffinized sections treated with the endogenous biotin-blocking kit (Invitrogen), staining (4°C, 12 h) with biotin-conjugated anti-PCNA, and incubation (25°C, 1 h) with Alexa Fluor 633-conjugated streptavidin. The sections on coverslips were washed and mounted on slides using VectaShield medium containing DAPI (Vector Labs.). Images were examined using a Leica TCS SP2 confocal microscope.

RESULTS

Role of p53 in JNK-regulated proliferation and contact growth inhibition.

It is established that compound deficiency of JNK1 plus JNK2 in murine embryo fibroblasts (MEF) causes rapid p53-dependent senescence (14, 46). Indeed, the senescence of Jnk1−/− Jnk2−/− MEF can be prevented by disruption of the p53 pathway (14). We therefore pre- pared MEF from Jnk1−/− Jnk2−/− Trp53−/− mice (Jnk−/− Trp53−/− MEF). As expected, these triple-knockout Jnk−/− Trp53−/− MEF proliferated rapidly when cultured in vitro.

Microscopic examination of exponentially growing cultures of WT, Trp53−/−, and Jnk−/− Trp53−/− primary MEF showed no major differences in cell morphologies (Fig. 1A). However, these cultures were markedly different when grown to high density. The WT MEF formed a growth-arrested monolayer at confluence (Fig. 1A). In contrast, the Trp53−/− MEF did not exhibit contact growth inhibition and formed densely packed cultures with multiple layers (Fig. 1A). The Trp53−/− overgrowth phenotype was strongly suppressed in confluent cultures of Jnk−/− Trp53−/− MEF (Fig. 1A). This conclusion was confirmed by measurement of cell numbers (Fig. 1B). Moreover, the effect of p53 deficiency to increase cell growth in low concentrations of serum was suppressed by JNK deficiency (Fig. 1B). To test the role of JNK in three-dimensional cultures of p53-deficient MEF, we examined the growth of cells in soft agar. WT cells did not grow in soft agar, but Trp53−/− MEF formed small colonies (Fig. 1C and D). JNK deficiency suppressed this effect of p53 deficiency to cause growth in soft agar (Fig. 1C and D). Together, these data demonstrate that the effect of p53 deficiency to cause loss of contact growth inhibition and proliferation in soft agar requires JNK.

Fig. 1.
Growth properties of Trp53−/− Jnk1−/− Jnk2−/− embryonic fibroblasts. (A) Loss of contact growth inhibition in Trp53−/− MEF cultures is prevented by disruption of Jnk1 plus Jnk2. Wild-type ...

JNK is required for Ras-induced suppression of contact growth inhibition.

We employed a conditional gene ablation strategy using primary MEF prepared from Rosa26-CreERT+/− Trp53LoxP/LoxP mice and Rosa26-CreERT+/− Trp53LoxP/LoxP Jnk1LoxP/LoxP Jnk2−/− mice to examine the effect of JNK plus p53 deficiency. The effect of activated KRas was examined using MEF prepared from mice that were heterozygous for the LoxP-Stop-LoxP KRasG12D (KRasLSL-G12D) allele. Cre-mediated recombination to ablate the floxed Trp53/Jnk1 alleles and to express the KRasG12D allele was initiated by treatment of the MEF with 4-hydoxytamoxifen. Comparison of Trp53−/− and Trp53−/− Jnk−/− MEF expressing KRasG12D demonstrated that JNK deficiency prevented the high-density growth of the MEF at confluence and prevented the formation of multiple cell layers (Fig. 2A). Together, these data demonstrate that JNK is required for Ras-induced suppression of contact growth inhibition.

Fig. 2.
Effect of JNK deficiency on cadherin expression. (A) MEF prepared from Rosa26-CreERT+/− Trp53LoxP/LoxP KRas+/LSL-G12D mice (Trp53−/− KrasG12D mice) and Rosa26-CreERT+/− Trp53LoxP/LoxP KRas+/LSL-G12D Jnk1LoxP/LoxP Jnk2−/− ...

Cadherins play an important role in homotypic cellular interactions (9). Expression of E-cadherin, N-cadherin, and OB-cadherin was detected in Trp53−/− and Jnk−/− Trp53−/− MEF (Fig. 2B). High levels of N-cadherin were found in Trp53−/− MEF (Fig. 2B). In contrast, Jnk−/− Trp53−/− MEF expressed less N-cadherin and more OB-cadherin than p53−/− MEF (Fig. 2B). Studies using MEF with activated Ras demonstrated decreased N-cadherin expression by p53−/− MEF and markedly increased expression of E-cadherin by Jnk−/− p53−/− MEF (Fig. 2B). Immunofluorescence analysis confirmed that activated Ras reduced N-cadherin expression by Trp53−/− MEF and that activated Ras increased E-cadherin expression by Trp53−/− Jnk−/− MEF (Fig. 2C). These changes in cadherin expression may contribute to the failure of Ras to suppress contact growth inhibition of Jnk−/− Trp53−/− MEF compared with that of Trp53−/− MEF (Fig. 1A and and2A2A).

Loss of E-cadherin has been associated with reduced cell-cell adhesion and accelerated progression to carcinoma (40). Increased E-cadherin expression by JNK-deficient cells (Fig. 2B and C) may therefore contribute to the increased contact growth inhibition of Ras-transformed MEF in vitro (Fig. 2A). To test this hypothesis, we examined the effect of increased expression of E-cadherin in control MEF and the expression of dominant negative (dn) E-cadherin in JNK-deficient MEF (Fig. 3A). These changes in E-cadherin did not alter cell morphology at confluence (Fig. 3B) or proliferation (Fig. 3C). However, increased expression of E-cadherin did suppress the growth of control Ras-transformed MEF in soft agar (Fig. 3D). Ras-transformed JNK-deficient MEF grew poorly in soft agar, but expression of dn-E-cadherin did not increase soft agar growth (Fig. 3D). Together, these data indicate that E-cadherin expression may only partially contribute to the phenotype of JNK-deficient MEF transformed by Ras.

Fig. 3.
Role of E-cadherin in KRas-mediated transformation of control and JNK-deficient MEF. (A) KRasG12D Trp53−/− MEF and KRasG12D Trp53−/− Jnk−/− MEF were transduced with recombinant retroviruses that express ...

The mechanism that accounts for the increased expression of E-cadherin by Ras-transformed JNK-deficient MEF is unclear. We detected increased expression of E-cadherin (Cdh1) mRNA by Ras-transformed JNK-deficient MEF compared with that by Ras-transformed control MEF (Fig. 2D). This observation indicates that JNK may function to repress E-cadherin gene expression. Previous studies have established that repressors, including Snail (Snai1) and Slug (Snai2), downregulate E-cadherin expression (4, 8, 24). Indeed, we found that the increased expression of E-cadherin by Ras-transformed JNK-deficient MEF was associated with significantly decreased expression of Slug (Fig. 2D). It is therefore possible that JNK-regulated expression of Slug may contribute to increased E-cadherin expression by Ras-transformed JNK-deficient MEF.

Role of p53 in JNK-mediated apoptosis.

It is established that the JNK signaling pathway contributes to the apoptotic response to some insults by activating the intrinsic (mitochondrial) pathway (46). The mechanism is mediated, in part, by phosphorylation of members of the Bcl2-related protein family, including Bim, Bmf, and Mcl-1 (26, 27, 38). This signaling pathway may influence tumor development (49).

A role for p53 in JNK-dependent apoptosis has been proposed (7, 20, 21). To test the requirement of p53 in JNK-mediated apoptosis, we examined the effect of UV radiation on JNK- and p53-deficient MEF (Fig. 4). UV-stimulated genomic DNA fragmentation assays demonstrated that both p53−/− MEF and Jnk−/− Trp53−/− MEF exhibited resistance to UV radiation (Fig. 4A). However, time course analysis of cell survival demonstrated that Trp53−/− MEF were partially resistant to UV radiation and that Jnk−/− Trp53−/− MEF exhibited significantly increased resistance to UV radiation (Fig. 4B). This conclusion was confirmed by the analysis of colony formation following exposure to UV radiation (Fig. 4C). These data demonstrate that JNK can regulate apoptosis independently of p53. To obtain biochemical evidence to support this conclusion, we examined UV-stimulated activation of caspase 3 and cleavage of the caspase substrate PARP (Fig. 4D). We found that p53 deficiency did not prevent caspase 3 activation, but caspase 3 activation was strongly suppressed in Jnk−/− Trp53−/− MEF. These data demonstrate that p53 is not required for JNK-dependent apoptosis. JNK deficiency may therefore contribute to tumor development in a p53-deficient genetic background by suppression of stress-induced apoptosis.

Fig. 4.
JNK suppresses stress-induced apoptosis in p53-deficient MEF. (A) MEF were exposed to the indicated doses of UV radiation. Lysates were prepared at 4 h postirradiation, and genomic DNA fragmentation was measured by ELISA. Statistically significant differences ...

JNK deficiency suppresses Ras-stimulated transformation in vitro.

The Trp53−/− and Jnk−/− Trp53−/− MEF represent genetically defined primary cells that can be employed to test the requirement of JNK for transformation by Ras in vitro (Fig. 4). Control studies confirmed the presence of a functional JNK signaling pathway in Trp53−/− MEF but not in Jnk−/− Trp53−/− MEF (Fig. 5A). Microscopic examination demonstrated that activated Ras caused p53−/− MEF to exhibit a spindle-shaped morphology, but this morphological change was reduced in Jnk−/− p53−/− MEF (Fig. 5B). Measurement of growth in response to different concentrations of serum demonstrated that activated Ras increased the saturation density of both Trp53−/− and Jnk−/− Trp53−/− MEF, although the JNK-deficient MEF exhibited less growth (especially in low serum concentrations) than p53−/− MEF (Fig. 5C). This conclusion was confirmed by direct measurement of cell proliferation in low (1%) and high (10%) serum concentrations (Fig. 5D and E).

Fig. 5.
Effect of activated Ras on Trp53−/− MEF and Trp53−/− Jnk−/− MEF. (A) MEF were exposed to 0 or 60 J/m2 UV-C, harvested at 60 min postirradiation, and examined by immunoblot analysis using antibodies to phospho-JNK ...

Since JNK deficiency did not prevent Ras-stimulated growth (Fig. 5), we questioned whether the loss of JNK might influence other signal transduction pathways in MEF with activated Ras. No significant differences in the activation of ERK, p38 MAP kinase, and AKT were detected when Trp53−/− and Jnk−/− Trp53−/− MEF were compared (Fig. 6A). However, we detected reduced levels of reactive oxygen species (ROS) in Jnk−/− Trp53−/− MEF compared with those in Trp53−/− MEF (Fig. 6B). The ROS in Trp53−/− MEF with activated Ras was suppressed by diphenyleneiodonium chloride (DPI), an inhibitor of NADPH oxidases (Nox) enzymes, but not by the mitochondrial electron transport inhibitor rotenone (Fig. 6C). These data are consistent with Nox-dependent, rather than mitochondrion-dependent, ROS accumulation (31, 51). Nox1 and Nox4 have been implicated in ROS production by MEF (17). JNK deficiency caused no change in the expression of Nox1 (data not shown), but JNK deficiency did cause reduced expression of Nox4 (Fig. 6D). Expression of the Nox enzyme subunit p22phox was not altered by JNK deficiency (Fig. 6D).

Fig. 6.
Ras-mediated signal transduction in Trp53−/− MEF and Trp53−/− Jnk−/− MEF. (A) MEF were exposed to 0 or 60 J/m2 UV-C and harvested at 60 min postirradiation. The amounts of phospho-p38 MAP kinase (p-p38), ...

ROS production has been implicated in tumorigenesis (44). The levels of ROS detected in Trp53−/− MEF being greater than those in Jnk−/− Trp53−/− MEF suggests that JNK deficiency may alter the tumorigenic potential of these MEF with activated Ras. To test this prediction, we examined the growth of these MEF in soft agar assays in vitro. We found that activated Ras caused growth of large colonies of Trp53−/− MEF in soft agar, but activated Ras did not cause the growth of large Jnk−/− Trp53−/− MEF colonies in soft agar (Fig. 7A and B). Retroviral transduction of Nox4 did not rescue the defect in soft agar growth or contact growth inhibition detected in cultures of Ras-transformed Jnk−/− Trp53−/− MEF (data not shown). This observation demonstrates that reduced expression of Nox4 is not sufficient to account for the phenotype of Ras-transformed JNK-deficient MEF.

Fig. 7.
JNK is required for colony formation in soft agar and tumor formation in vivo. (A, B) Ras-transformed MEF and (Trp53−/− Jnk−/− MEF were treated with 1 μM 4-hydroxy-tamoxifen (24 h). The MEF were plated in soft agar ...

To test the effect of JNK deficiency on tumor formation in vivo, we examined the subcutaneous growth of MEF with activated Ras in syngeneic mice. We found that Ras-transformed Trp53−/− MEF formed tumors, but this growth was strongly suppressed by JNK deficiency (Fig. 7C and D). Together, these data demonstrate that JNK is required for Ras-induced transformation of p53-deficient MEF in vitro.

JNK deficiency suppresses Ras-induced lung tumor formation in vivo.

In vitro studies suggest that JNK is required for Ras-stimulated transformation (Fig. 7). To test whether JNK contributes to Ras-stimulated transformation in vivo, we examined the effect of activated Ras in an established model of lung tumorigenesis (29). Lung-specific expression of KRasG12D was studied using nasal instillation of adenovirus-Cre (29). We compared the effect of endogenous KRas activation in Jnk1+/+ Jnk2+/+ (control) mice and in mice with conditional compound JNK deficiency (Jnk1LoxP/LoxP Jnk2−/−). Expression of KRasG12D caused lesions in the lungs, including atypical adenomatous hyperplasia, epithelial hyperplasia of bronchioles, and adenomas (Fig. 8A and B). Comparison of control mice with JNK-deficient mice demonstrated that the number of hyperplastic lesions and adenomas was greatly reduced in the JNK-deficient mice (Fig. 8C and D). Immunofluorescence analysis of lung sections demonstrated that JNK deficiency caused a marked decrease in staining for the proliferation marker PCNA (Fig. 8E). No major differences in apoptosis markers (caspase 3 activation and PARP cleavage) between control and JNK-deficient lungs were detected (Fig. 8F). These data demonstrate that JNK is required for the efficient formation of Ras-induced lesions in the lung. The major role of JNK is reflected by increased proliferation rather than altered apoptosis.

Fig. 8.
JNK is required for Ras-induced lung tumorigenesis. (A) KRas+/LSL-G12D mice (control KRasG12D mice) and KRas+/LSL-G12D Jnk1LoxP/LoxP Jnk2−/− mice (KRasG12D Jnk−/− mice) were exposed to adenovirus-Cre by nasal instillation. ...

The low level of lung tumorigenesis detected in JNK-deficient mice suggests that JNK may not be essential for Ras-induced lung cancer. These tumors may represent JNK-independent formation of lung cancer. Alternatively, these tumors may arise because of incomplete Cre-mediated ablation of Jnk genes. Indeed, the possible presence of incomplete gene ablation in this model of KRas-induced lung cancer is consistent with previous reports using Rac1LoxP/LoxP mice (33). We tested whether incomplete Jnk gene ablation might contribute to the low level of tumorigenesis in JNK-deficient mice by genotype analysis of genomic DNA isolated from these tumors. This analysis demonstrated that all of the JNK-deficient lung tumors examined retained a Jnk1LoxP allele (Fig. 9). Indeed, immunofluorescence analysis of the phosphorylation of the JNK substrate c-Jun on Ser63 demonstrated that the JNK-deficient tumors retained a functional JNK signaling pathway (Fig. 9). We did not find in JNK-deficient mice any tumors that lacked expression of the Jnk1LoxP allele or phosphorylation of the JNK substrate c-Jun. These data indicate that JNK may be essential for KRas-induced lung tumorigenesis.

Fig. 9.
Analysis of lung tumors detected in JNK-deficient mice. Nasal instillation of adenovirus-Cre was performed using control KRas+/LSL-G12D mice and JNK-deficient Jnk1LoxP/LoxP Jnk2−/− KRas+/LSL-G12D mice. Cre-mediated ablation of the LoxP-Stop-LoxP ...

DISCUSSION

This study demonstrates that JNK can play a major role in Ras-induced tumor formation. Specifically, JNK is essential for transformation of primary p53−/− MEF by activated Ras in vitro. Moreover, JNK is required in a mouse model of Ras-induced lung tumor formation in vivo. Together, these data provide strong evidence that the JNK signaling pathway may contribute to the development of cancer.

Further studies are needed to identify the signaling pathway that leads to Ras-induced JNK signaling. A recent study established that Rac1 is required for Ras-induced lung tumor formation (33). Since Rac1 can cause JNK activation (3, 12, 37), it is possible that this role of Rac1 may reflect a requirement of Rac1 for JNK activation in this model of Ras-induced lung tumorigenesis. Targets of Rac1 that may mediate JNK pathway activation include members of the mixed-lineage protein kinase family (22).

Additional studies are required to identify JNK substrates that are relevant to lung tumorigenesis. It is possible that AP1 family transcription factors, which are activated by JNK, may contribute to Ras-induced lung tumor formation. However, many other targets of JNK signaling, in both the cytoplasm and the nucleus, may contribute to JNK-dependent tumorigenesis (48). Detailed analysis of these JNK substrates is required to identify those relevant to lung tumorigenesis.

JNK prevents contact growth inhibition.

JNK may contribute to dysregulated cellular proliferation by interfering with contact growth inhibition. Trp53−/− and Trp53−/− KRasG12D primary MEF exhibit defects in contact growth inhibition and form multiple layers when grown to confluence (Fig. 1A and and2A).2A). In contrast, compound deficiency of Jnk1 plus Jnk2 prevents the overgrowth phenotype of both Trp53−/− and Trp53−/− KRasG12D primary MEF (Fig. 1A and and2A).2A). This effect of JNK correlates with altered expression of the cadherin family of adhesion proteins (Fig. 2B and C). Strikingly, Ras-transformed Trp53−/− Jnk−/− primary MEF express high levels of E-cadherin (Fig. 2B and C). This expression of E-cadherin may contribute to increased intercellular adhesion. Moreover, in the context of Ras-induced epithelial cell tumorigenesis, increased E-cadherin expression might decrease epithelial-mesenchymal transition (EMT) and progression to carcinoma (5). Indeed, it is established that EMT of lung epithelium is suppressed by JNK deficiency (1). These actions of JNK to decrease the intercellular adhesion of cells expressing KRasG12D may contribute to tumor formation.

JNK and the tumor microenvironment.

This study has focused on the role of JNK in tumor cells. However, JNK may also play roles within the tumor microenvironment, including expression of cytokines/growth factors (15) and the function of the innate and adaptive immune systems (15, 23, 45). Thus, the finding that Jnk1−/− mice exhibit decreased (and Jnk2−/− mice exhibit increased) carcinogen-induced skin cancer compared with wild-type mice (11, 42) may be explained, in part, by the opposite effects of JNK1 and JNK2 deficiency on CD8 T cell-mediated tumor immunosurveillance (23, 45). Moreover, the effects of JNK1 deficiency to suppress carcinogen-induced hepatocellular carcinoma (28) may be accounted for, in part, by decreased expression of inflammatory cytokines (e.g., interleukin 6 [IL-6] and tumor necrosis factor [TNF]) by hepatic innate immune cells (15). These considerations indicate that a full understanding of the role of JNK in cancer should take account of JNK functions in both tumor cells and the tumor microenvironment.

JNK and tumor suppression.

The results of this study demonstrate that Ras-induced transformation of primary MEF and Ras-induced lung tumor formation requires JNK. However, these data do not exclude the possibility that JNK may also contribute to tumor suppression. Indeed, published studies have implicated JNK in both tumor formation and tumor suppression (16, 49). Precedent for this type of dual activity during tumor development is provided by the transforming growth factor β (TGF-β) pathway (43). Roles of the JNK pathway in tumor suppression most often correlate with late-stage tumor metastasis (49). Indeed, studies of human cancer genetics and biochemical analysis of human tumor-derived cell lines support the conclusion that the JNK signal transduction pathway may contribute to metastasis suppression (49). Moreover, Ras transformation of established cell lines demonstrates that loss of JNK can cause increased metastatic potential (32). Further studies will be required to formally test the hypothesis that JNK may act as a suppressor of late-stage tumor development in vivo. In contrast, this study demonstrates that JNK is required for early stage Ras-induced tumor formation in vitro and in vivo.

ACKNOWLEDGMENTS

We thank Heather Armata and Hayla Sluss for backcrossing the floxed Trp53 mice to the C57BL/6J strain, David Garlick (University of Massachusetts Medical School) for pathological examination of tissue sections, John Keaney (University of Massachusetts Medical School) for providing the Nox4 cDNA, Tammy Barrett for expert technical assistance, and Kathy Gemme for administrative assistance.

These studies were supported by a grant from the National Institutes of Health (R01-CA65861). R.J.D. and T.J. are Investigators of the Howard Hughes Medical Institute. R.J.D. is also a member of the Diabetes and Endocrinology Research Center of the University of Massachusetts Medical School, which is funded by the National Institutes of Health grant P30-DK32520.

Footnotes

[down-pointing small open triangle]Published ahead of print on 31 January 2011.

The authors have paid a fee to allow immediate free access to this article.

REFERENCES

1. Alcorn J. F., et al. 2008. Jun N-terminal kinase 1 regulates epithelial-to-mesenchymal transition induced by TGF-beta1. J. Cell Sci. 121:1036–1045. [PMC free article] [PubMed]
2. Badea T. C., Wang Y., Nathans J. 2003. A noninvasive genetic/pharmacologic strategy for visualizing cell morphology and clonal relationships in the mouse. J. Neurosci. 23:2314–2322. [PubMed]
3. Bagrodia S., Derijard B., Davis R. J., Cerione R. A. 1995. Cdc42 and PAK-mediated signaling leads to Jun kinase and p38 mitogen-activated protein kinase activation. J. Biol. Chem. 270:27995–27998. [PubMed]
4. Batlle E., et al. 2000. The transcription factor snail is a repressor of E-cadherin gene expression in epithelial tumour cells. Nat. Cell Biol. 2:84–89. [PubMed]
5. Berx G., van Roy F. 2009. Involvement of members of the cadherin superfamily in cancer. Cold Spring Harb. Perspect. Biol. 1:a003129. [PMC free article] [PubMed]
6. Bost F., et al. 1999. The Jun kinase 2 isoform is preferentially required for epidermal growth factor-induced transformation of human A549 lung carcinoma cells. Mol. Cell. Biol. 19:1938–1949. [PMC free article] [PubMed]
7. Buschmann T., et al. 2001. Jun NH2-terminal kinase phosphorylation of p53 on Thr-81 is important for p53 stabilization and transcriptional activities in response to stress. Mol. Cell. Biol. 21:2743–2754. [PMC free article] [PubMed]
8. Cano A., et al. 2000. The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression. Nat. Cell Biol. 2:76–83. [PubMed]
9. Cavey M., Lecuit T. 2009. Molecular bases of cell-cell junctions stability and dynamics. Cold Spring Harb. Perspect. Biol. 1:a002998. [PMC free article] [PubMed]
10. Chen K., Kirber M. T., Xiao H., Yang Y., Keaney J. F., Jr 2008. Regulation of ROS signal transduction by NADPH oxidase 4 localization. J. Cell Biol. 181:1129–1139. [PMC free article] [PubMed]
11. Chen N., et al. 2001. Suppression of skin tumorigenesis in c-Jun NH(2)-terminal kinase-2-deficient mice. Cancer Res. 61:3908–3912. [PubMed]
12. Coso O. A., et al. 1995. The small GTP-binding proteins Rac1 and Cdc42 regulate the activity of the JNK/SAPK signaling pathway. Cell 81:1137–1146. [PubMed]
13. Cui J., et al. 2006. c-Jun NH(2)-terminal kinase 2alpha2 promotes the tumorigenicity of human glioblastoma cells. Cancer Res. 66:10024–10031. [PubMed]
14. Das M., et al. 2007. Suppression of p53-dependent senescence by the JNK signal transduction pathway. Proc. Natl. Acad. Sci. U. S. A. 104:15759–15764. [PubMed]
15. Das M., et al. 2009. Induction of hepatitis by JNK-mediated expression of TNF-alpha. Cell 136:249–260. [PMC free article] [PubMed]
16. Davis R. J. 2000. Signal transduction by the JNK group of MAP kinases. Cell 103:239–252. [PubMed]
17. Dolado I., et al. 2007. p38alpha MAP kinase as a sensor of reactive oxygen species in tumorigenesis. Cancer Cell 11:191–205. [PubMed]
18. Donehower L. A., et al. 1992. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 356:215–221. [PubMed]
19. Dong C., et al. 1998. Defective T cell differentiation in the absence of Jnk1. Science 282:2092–2095. [PubMed]
20. Fuchs S. Y., et al. 1998. JNK targets p53 ubiquitination and degradation in nonstressed cells. Genes Dev. 12:2658–2663. [PubMed]
21. Fuchs S. Y., Adler V., Pincus M. R., Ronai Z. 1998. MEKK1/JNK signaling stabilizes and activates p53. Proc. Natl. Acad. Sci. U. S. A. 95:10541–10546. [PubMed]
22. Gallo K. A., Johnson G. L. 2002. Mixed-lineage kinase control of JNK and p38 MAPK pathways. Nat. Rev. Mol. Cell Biol. 3:663–672. [PubMed]
23. Gao Y., et al. 2005. JNK1 is essential for CD8+ T cell-mediated tumor immune surveillance. J. Immunol. 175:5783–5789. [PubMed]
24. Hajra K. M., Chen D. Y., Fearon E. R. 2002. The SLUG zinc-finger protein represses E-cadherin in breast cancer. Cancer Res. 62:1613–1618. [PubMed]
25. Hess P., Pihan G., Sawyers C. L., Flavell R. A., Davis R. J. 2002. Survival signaling mediated by c-Jun NH(2)-terminal kinase in transformed B lymphoblasts. Nat. Genet. 32:201–205. [PubMed]
26. Hubner A., Barrett T., Flavell R. A., Davis R. J. 2008. Multisite phosphorylation regulates Bim stability and apoptotic activity. Mol. Cell 30:415–425. [PMC free article] [PubMed]
27. Hubner A., Cavanagh-Kyros J., Rincon M., Flavell R. A., Davis R. J. 2010. Functional cooperation of the proapoptotic Bcl2 family proteins Bmf and Bim in vivo. Mol. Cell. Biol. 30:98–105. [PMC free article] [PubMed]
28. Hui L., Zatloukal K., Scheuch H., Stepniak E., Wagner E. F. 2008. Proliferation of human HCC cells and chemically induced mouse liver cancers requires JNK1-dependent p21 downregulation. J. Clin. Invest. 118:3943–3953. [PMC free article] [PubMed]
29. Jackson E. L., et al. 2001. Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-Ras. Genes Dev. 15:3243–3248. [PubMed]
30. Jaeschke A., et al. 2006. JNK2 is a positive regulator of the cJun transcription factor. Mol. Cell 23:899–911. [PubMed]
31. Kamata H., Hirata H. 1999. Redox regulation of cellular signalling. Cell. Signal. 11:1–14. [PubMed]
32. Kennedy N. J., et al. 2003. Suppression of Ras-stimulated transformation by the JNK signal transduction pathway. Genes Dev. 17:629–637. [PubMed]
33. Kissil J. L., et al. 2007. Requirement for Rac1 in a K-Ras induced lung cancer in the mouse. Cancer Res. 67:8089–8094. [PubMed]
34. Kuan C. Y., et al. 1999. The Jnk1 and Jnk2 protein kinases are required for regional specific apoptosis during early brain development. Neuron 22:667–676. [PubMed]
35. Lamb J. A., Ventura J. J., Hess P., Flavell R. A., Davis R. J. 2003. JunD mediates survival signaling by the JNK signal transduction pathway. Mol. Cell 11:1479–1489. [PubMed]
36. Marino S., Vooijs M., van Der Gulden H., Jonkers J., Berns A. 2000. Induction of medulloblastomas in p53-null mutant mice by somatic inactivation of Rb in the external granular layer cells of the cerebellum. Genes Dev. 14:994–1004. [PubMed]
37. Minden A., Lin A., Claret F. X., Abo A., Karin M. 1995. Selective activation of the JNK signaling cascade and c-Jun transcriptional activity by the small GTPases Rac and Cdc42Hs. Cell 81:1147–1157. [PubMed]
38. Morel C., Carlson S. M., White F. M., Davis R. J. 2009. Mcl-1 integrates the opposing actions of signaling pathways that mediate survival and apoptosis. Mol. Cell. Biol. 29:3845–3852. [PMC free article] [PubMed]
39. Onder T. T., et al. 2008. Loss of E-cadherin promotes metastasis via multiple downstream transcriptional pathways. Cancer Res. 68:3645–3654. [PubMed]
40. Perl A. K., Wilgenbus P., Dahl U., Semb H., Christofori G. 1998. A causal role for E-cadherin in the transition from adenoma to carcinoma. Nature 392:190–193. [PubMed]
41. Potapova O., et al. 2000. c-Jun N-terminal kinase is essential for growth of human T98G glioblastoma cells. J. Biol. Chem. 275:24767–24775. [PubMed]
42. She Q. B., Chen N., Bode A. M., Flavell R. A., Dong Z. 2002. Deficiency of c-Jun-NH(2)-terminal kinase-1 in mice enhances skin tumor development by 12-O-tetradecanoylphorbol-13-acetate. Cancer Res. 62:1343–1348. [PubMed]
43. Siegel P. M., Massague J. 2003. Cytostatic and apoptotic actions of TGF-beta in homeostasis and cancer. Nat. Rev. Cancer 3:807–821. [PubMed]
44. Suh Y. A., et al. 1999. Cell transformation by the superoxide-generating oxidase Mox1. Nature 401:79–82. [PubMed]
45. Tao J., et al. 2007. JNK2 negatively regulates CD8+ T cell effector function and anti-tumor immune response. Eur. J. Immunol. 37:818–829. [PubMed]
46. Tournier C., et al. 2000. Requirement of JNK for stress-induced activation of the cytochrome c-mediated death pathway. Science 288:870–874. [PubMed]
47. Ventura J. J., Kennedy N. J., Lamb J. A., Flavell R. A., Davis R. J. 2003. c-Jun NH(2)-terminal kinase is essential for the regulation of AP-1 by tumor necrosis factor. Mol. Cell. Biol. 23:2871–2882. [PMC free article] [PubMed]
48. Weston C. R., Davis R. J. 2007. The JNK signal transduction pathway. Curr. Opin. Cell Biol. 19:142–149. [PubMed]
49. Whitmarsh A. J., Davis R. J. 2007. Role of mitogen-activated protein kinase kinase 4 in cancer. Oncogene 26:3172–3184. [PubMed]
50. Whitmarsh A. J., Davis R. J. 1996. Transcription factor AP-1 regulation by mitogen-activated protein kinase signal transduction pathways. J. Mol. Med. 74:589–607. [PubMed]
51. Wu R. F., Terada L. S. 2009. Ras and Nox: linked signaling networks? Free Radic. Biol. Med. 47:1276–1281. [PMC free article] [PubMed]
52. Yang D. D., et al. 1998. Differentiation of CD4+ T cells to Th1 cells requires MAP kinase JNK2. Immunity 9:575–585. [PubMed]
53. Yang Y. M., et al. 2003. c-Jun NH(2)-terminal kinase mediates proliferation and tumor growth of human prostate carcinoma. Clin. Cancer Res. 9:391–401. [PubMed]

Articles from Molecular and Cellular Biology are provided here courtesy of American Society for Microbiology (ASM)